Advertisement

Topics

A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base

2014-08-27 03:38:58 | BioPortfolio

Summary

The purpose of this study is to determine recurrence rates of nodular Basal Cell Carcinomas on the face removed with curettage and electrodessication (cautery) followed by application of Imiquimod cream to the base and further to achieve lower recurrence rates than after treatment with curettage and electrodessication alone.

Description

Basal Cell Carcinomas (BCC) are the commonest form of skin cancer in the white population. The face is where they most frequently occur and the nodular BCCs are the commonest type. Curettage and cautery/electrodessication (C&C) has been an established way of management of nodular BCCs for years, being a simple surgical procedure readily performed in outpatient clinics with good aesthetic results and high cure rates. The purpose of this study is to determine recurrence rates of nodular BCCs on the face removed with C&C followed by application of Imiquimod cream to the base and further to achieve lower recurrence rates than after treatment with C&C alone. Imiquimod is an immune response modifier with anti-tumour effects already licensed for the treatment of superficial BCCs in the UK.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Basal Cell Carcinoma

Intervention

Imiquimod cream, curettage and cautery

Location

Dermatology Department, Western Infirmary
Glasgow
Lanarkshire
United Kingdom
G11 6NT

Status

Not yet recruiting

Source

University of Glasgow

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:38:58-0400

Clinical Trials [2066 Associated Clinical Trials listed on BioPortfolio]

A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence

The primary objective of this study is to assess whether basal cell carcinoma (BCC) lesions surgically treated with curettage, followed by imiquimod 5% cream as postsurgical adjuvant thera...

Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage

To assess the efficacy of treating a nodular basal cell carcinoma with imiquimod cream after initial treatment with curettage

Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma

This study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.

Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1

The purpose of this study is to determine if imiquimod cream can reverse the growth of neurofibromas. Imiquimod is a skin cream that works by stimulating the body's immune system to respo...

A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma

The purpose of this study is to evaluate the long-term sustained clearance rate of superficial basal cell carcinoma during a 5 year period following treatment with imiquimod

PubMed Articles [18664 Associated PubMed Articles listed on BioPortfolio]

Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod and topical 5-fluorouracil in patients with superficial basal cell carcinoma.

For the treatment of superficial basal cell carcinoma, a prospective non-inferiority randomized controlled multicenter trial with 601 patients showed that 5% imiquimod cream was superior and 5-fluorou...

Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma.

Imiquimod 5% topical cream is approved for treatment of superficial basal cell carcinoma (BCC). Data on the long-term efficacy and usage in other BCC subtypes are scarce.

Methyl-aminolevulinate Photodynamic Therapy combined with curettage debulking for pigmented Basal Cell Carcinoma.

Basal cell carcinoma (BCC) is the most common skin cancer, with an incidence rate in Spain of 113.05 cases per 100 000 person-years (CI95%, 89.03-137.08).(1) Pigmented BCCs (pBCCs), is a clinical and...

Practical indications for the management of non--melanoma skin cancer patients.

Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), together encompassed in the term non--melanoma skin cancers (NMSC), are the most common cancers among fair--skinned populations. Individua...

Acquired progressive lymphangioma: Case report with partial response to imiquimod 5% cream.

Acquired progressive lymphangioma (APL), or benign lymphangioendothelioma, is an unusual entity derived from vascular structures. Clinically and histopathologically it may resemble Kaposi's sarcoma an...

Medical and Biotech [MESH] Definitions

A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)

A patched receptor that may function redundantly with the PATCHED-1 RECEPTOR to modulate hedgehog signaling. It may also play a role in epidermal development and as a TUMOR SUPPRESSOR PROTEIN. Mutations in the patched-2 gene are associated with BASAL CELL NEVUS SYNDROME; CARCINOMA, BASAL CELL; and MEDULLOBLASTOMA.

A skin carcinoma that histologically exhibits both basal and squamous elements. (From Dorland, 27th ed)

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.

More From BioPortfolio on "A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base"

Quick Search
Advertisement
 

Relevant Topic

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...


Searches Linking to this Trial